Total Payments
$17.7M
2024 Payments
$1,786
Companies
74
Transactions
327
Medicare Patients
5,990
Medicare Billing
$4.5M
Payment Breakdown by Category
Other$17.7M (100.0%)
Food & Beverage$5,536 (0.0%)
Travel$423.15 (0.0%)
Gifts$33.10 (0.0%)
Education$21.13 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Current or prospective ownership or investment interest | $16.6M | 3 | 94.0% |
| Acquisitions | $1.0M | 2 | 5.9% |
| Food and Beverage | $5,536 | 318 | 0.0% |
| Travel and Lodging | $423.15 | 2 | 0.0% |
| Gift | $33.10 | 1 | 0.0% |
| Education | $21.13 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boston Scientific Corporation | $17.7M | 5 | $0 (2022) |
| US Oncology Corporate, Inc. | $841.68 | 4 | $0 (2024) |
| Janssen Biotech, Inc. | $454.10 | 27 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $387.23 | 23 | $0 (2024) |
| Daiichi Sankyo Inc. | $277.66 | 16 | $0 (2024) |
| Merck Sharp & Dohme LLC | $204.11 | 13 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $192.05 | 12 | $0 (2024) |
| Seagen Inc. | $186.43 | 11 | $0 (2023) |
| Lilly USA, LLC | $160.00 | 10 | $0 (2024) |
| Exelixis Inc. | $158.50 | 10 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,786 | 56 | US Oncology Corporate, Inc. ($841.68) |
| 2023 | $961.83 | 55 | Janssen Biotech, Inc. ($162.81) |
| 2022 | $681,606 | 46 | Boston Scientific Corporation ($680,844) |
| 2021 | $368,693 | 51 | BOSTON SCIENTIFIC CORPORATION ($367,941) |
| 2020 | $798,065 | 26 | Boston Scientific Corporation ($797,706) |
| 2019 | $517.26 | 33 | Pharmacyclics LLC, An AbbVie Company ($59.61) |
| 2018 | $15.8M | 26 | BOSTON SCIENTIFIC CORPORATION ($15.8M) |
| 2017 | $501.77 | 34 | Varian Medical Systems, Inc. ($51.49) |
All Payment Transactions
327 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Novocure Inc. | Optune Lua (NovoTTF-200T) (Device) | Food and Beverage | Cash or cash equivalent | $18.53 | General |
| Category: Oncology | ||||||
| 12/13/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $15.83 | General |
| Category: Iron Deficiency Anemia | ||||||
| 12/12/2024 | pharmaand GmbH | Rubraca (Drug) | Food and Beverage | Cash or cash equivalent | $18.97 | General |
| Category: PARP inhibitor | ||||||
| 12/10/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $23.60 | General |
| Category: Oncology | ||||||
| 11/26/2024 | Coherus Biosciences Inc. | Udenyca (Biological), LOQTORZI | Food and Beverage | In-kind items and services | $20.51 | General |
| Category: Granulocyte colony stimulating factor | ||||||
| 11/25/2024 | Myriad Genetic Laboratories, Inc. | MYRISK (Device) | Food and Beverage | In-kind items and services | $16.52 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $17.89 | General |
| Category: Oncology | ||||||
| 11/05/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $18.98 | General |
| Category: Oncology | ||||||
| 11/04/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $15.51 | General |
| Category: Oncology | ||||||
| 10/17/2024 | US Oncology Corporate, Inc. | — | Food and Beverage | Cash or cash equivalent | $402.00 | General |
| 10/17/2024 | US Oncology Corporate, Inc. | — | Travel and Lodging | Cash or cash equivalent | $371.66 | General |
| 10/17/2024 | US Oncology Corporate, Inc. | — | Gift | Cash or cash equivalent | $33.10 | General |
| 10/16/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $14.75 | General |
| 10/08/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $20.72 | General |
| Category: Oncology | ||||||
| 10/02/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $17.06 | General |
| Category: Oncology | ||||||
| 09/25/2024 | Lilly USA, LLC | VERZENIO (Drug), JAYPIRCA | Food and Beverage | In-kind items and services | $15.75 | General |
| Category: Oncology | ||||||
| 09/18/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $23.52 | General |
| Category: Oncology | ||||||
| 09/09/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $13.32 | General |
| Category: ONCOLOGY | ||||||
| 09/06/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $21.33 | General |
| Category: ONCOLOGY | ||||||
| 08/27/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $20.87 | General |
| Category: ONCOLOGY | ||||||
| 08/13/2024 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $18.74 | General |
| Category: Oncology | ||||||
| 08/05/2024 | Pharmacosmos Therapeutics Inc. | COSELA (Drug) | Food and Beverage | In-kind items and services | $17.05 | General |
| Category: HEMATOLOGY | ||||||
| 07/31/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $22.72 | General |
| Category: Oncology | ||||||
| 07/29/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $34.56 | General |
| Category: Oncology | ||||||
| 07/22/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $22.41 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 37 | 1,467 | 46,970 | $3.6M | $1.2M |
| 2022 | 36 | 1,316 | 28,698 | $3.8M | $1.3M |
| 2021 | 42 | 1,484 | 58,126 | $2.7M | $860,522 |
| 2020 | 48 | 1,723 | 50,476 | $4.0M | $1.2M |
Total Patients
5,990
Total Services
184,270
Medicare Billing
$4.5M
Procedure Codes
163
All Medicare Procedures & Services
163 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 199 | 477 | $1.7M | $566,981 | 33.0% |
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 14 | 5,203 | $624,000 | $224,720 | 36.0% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 204 | 494 | $321,100 | $141,464 | 44.1% |
| 77373 | Cranial lesion surgery using radiation over multiple sessions | Office | 2023 | 14 | 58 | $247,080 | $47,090 | 19.1% |
| 77301 | High precision radiation therapy planning | Office | 2023 | 26 | 27 | $140,400 | $39,854 | 28.4% |
| 77014 | Ct guidance for insertion of radiation therapy fields | Office | 2023 | 12 | 200 | $68,000 | $19,430 | 28.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 77 | 139 | $37,113 | $13,228 | 35.6% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 17 | 13,500 | $40,500 | $11,841 | 29.2% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 64 | 116 | $41,528 | $11,642 | 28.0% |
| 77338 | Design and construction of radiation treatment device for high precision radiation therapy | Office | 2023 | 26 | 29 | $37,729 | $10,789 | 28.6% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 27 | 53 | $41,658 | $9,871 | 23.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 102 | 167 | $30,227 | $9,639 | 31.9% |
| 77427 | Radiation treatment management, 5 treatment sessions | Office | 2023 | 18 | 60 | $27,720 | $9,032 | 32.6% |
| 77300 | Calculation of radiation therapy dose | Office | 2023 | 34 | 141 | $23,970 | $7,321 | 30.5% |
| 77334 | Design and construction of complex radiation treatment device | Office | 2023 | 26 | 71 | $23,288 | $7,129 | 30.6% |
| 77435 | Management of cranial lesion surgery using radiation over multiple sessions | Office | 2023 | 12 | 13 | $20,332 | $6,559 | 32.3% |
| Q5110 | Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | Office | 2023 | 13 | 23,520 | $23,520 | $6,120 | 26.0% |
| 77336 | Continuing radiation therapy consultation per week | Office | 2023 | 31 | 74 | $17,760 | $5,091 | 28.7% |
| 71260 | Ct scan of chest with contrast | Office | 2023 | 39 | 60 | $29,700 | $4,896 | 16.5% |
| 77263 | Complex radiation therapy planning | Office | 2023 | 32 | 33 | $19,800 | $4,373 | 22.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 38 | 74 | $13,616 | $3,718 | 27.3% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 50 | 176 | $8,096 | $2,170 | 26.8% |
| 96374 | Injection of drug or substance into vein | Office | 2023 | 30 | 64 | $7,488 | $1,899 | 25.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 69 | 166 | $8,632 | $1,836 | 21.3% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 22 | 22 | $2,398 | $983.18 | 41.0% |
About Dr. William Noyes, M.D
Dr. William Noyes, M.D is a Radiation Oncology healthcare provider based in Grand Forks, North Dakota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1649382292.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. William Noyes, M.D has received a total of $17.7M in payments from pharmaceutical and medical device companies, with $1,786 received in 2024. These payments were reported across 327 transactions from 74 companies. The most common payment nature is "Current or prospective ownership or investment interest" ($16.6M).
As a Medicare-enrolled provider, Noyes has provided services to 5,990 Medicare beneficiaries, totaling 184,270 services with total Medicare billing of $4.5M. Data is available for 4 years (2020–2023), covering 163 distinct procedure/service records.
Ad
Practice Information
- Specialty Radiation Oncology
- Other Specialties Radiation Oncology
- Location Grand Forks, ND
- Active Since 08/31/2006
- Last Updated 08/14/2020
- Taxonomy Code 2085R0001X
- Entity Type Individual
- NPI Number 1649382292
Products in Payments
- GENERAL THERAPIES (Device) $15.8M
- GENERAL - THERAPIES (Device) $797,706
- General - Therapies (Device) $680,844
- GENERAL THERAPIES (Device) $367,941
- ADCETRIS (Biological) $208.07
- KEYTRUDA (Biological) $187.76
- Enhertu (Drug) $166.36
- ERLEADA (Drug) $132.10
- BESREMI (Drug) $127.56
- Lenvima (Drug) $117.79
- Cabometyx (Drug) $117.28
- VERZENIO (Drug) $116.54
- DARZALEX (Biological) $109.52
- Imbruvica (Drug) $85.80
- JAKAFI (Drug) $85.68
- MONJUVI (Drug) $74.89
- INJECTAFER (Drug) $73.58
- ENHERTU (Biological) $72.59
- SOMATULINE DEPOT (Drug) $71.21
- COSELA (Drug) $70.25
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.